The MIB Agents OutSmarting Osteosarcoma Research Grant Program 2027 supports research aimed at advancing new knowledge, treatments, and better outcomes for patients with osteosarcoma.
The 2027 program offers two one-year funding mechanisms: the OutSmarting Osteosarcoma Hero Award, providing $100,000, and the Young Investigator (YI) Hope Award, providing $50,000 for early-career investigators. Since launching in 2017, the program has awarded $2.9 million to 37 investigators working in osteosarcoma research.
Eligibility Criteria
- The 2027 awards are open to investigators based in the United States and Canada.
- The Hero Award is intended for investigators proposing a compelling research study capable of advancing outcomes for osteosarcoma patients.
- The Young Investigator Hope Award is specifically designed to support early-career researchers.
- Proposed work must have a clear and meaningful focus on osteosarcoma research.
- Applicants should consult the 2027 Program Guidelines for the detailed PI rank, degree, institutional, and Young Investigator eligibility requirements before submission, as those details are not fully reproduced on the public program overview page.
Funding Details
- OutSmarting Osteosarcoma Hero Award: $100,000.
- Award duration: 1 year.
- OutSmarting Osteosarcoma Young Investigator Hope Award: $50,000.
- Award duration: 1 year.
Deadline
- LOI submission opens: September 9, 2026.
- LOI deadline: October 16, 2026.
- Approved LOI applicants notified: Early December 2026.
- Invited full application deadline: January 25, 2027.
- Grant period: July 1, 2027–June 30, 2028.
Further Information
- MIB Agents reports $2.9 million awarded to 37 investigators through the program to date.
- Program questions may be directed to kat@mibagents.org.
- Official program page: View the OutSmarting Osteosarcoma program
- Application portal: Apply through ProposalCentral